



New Hope for Brain Cancer Patients: A Medical Device with Multiple Tumor Targets

(PHOENIX AZ, August 15, 2025) Brain tumors are among the most dreaded and deadly forms of cancer. Despite decades of clinical trials, the present treatment options of surgical removal, radiation, and/or drug treatment have only extended life by months. Now however, a new bioengineered device will soon be entering Phase II clinical trials, giving much needed hope to those suffering from brain cancers.

In a paper just published in the premiere journal *Cancers*, Dr. Gary Arendash of RF Longevity presents the encouraging clinical evidence for why Transcranial Radiofrequency Wave Treatment (TRFT) should induce brain tumor regression and long-term patient survival. TRFT is self-administered at home for 1-hour treatments daily, has no apparent side effects, and has already been shown to stop and reverse Alzheimer's Disease cognitive decline in small studies.

The specific system of radiofrequency wave treatment employed by TRFT treats the entire human brain and doesn't just have one mechanism of action against brain tumors, but apparently has three: 1) Enhancement of lymphatic flow from the brain tumor out of the brain to increase immune attack on the tumor, 2) a re-balancing of the immune system in the brain to reduce brain inflammation, thus providing an inhospitable environment for the brain tumor, and 3) direct suppression of tumor cell viability.

Therefore, TRFT has multiple targets and thus multiple chances to induce tumor regression resulting in long-term patient survival. Dr. Arendash thinks that TRFT could be effective against both primary brain tumors (such as glioblastomas) and those arising from metastasis to the brain from other sites in the body such as the lung, breast, or colon. Moreover, TRFT could possibly treat brain tumors not yet large enough to be seen with current brain imaging technology because it enters all cells in the human brain.

Dr. Arendash strongly believes that the clinical evidence he and his colleagues attained since 2019 in association with NeuroEM Therapeutics, Inc. clearly warrants an immediate Phase II clinical trial in brain cancer patients. It will be up to the selected clinical site to determine the composition of brain cancer patients that will be enrolled in the TRFT clinical trial. Dr. Arendash indicated that the clinical site will be a leading brain cancer research center.

This bioengineered technology is unique in being safe long-term, involving in-home treatment, and attacking multiple aspects of brain tumor pathophysiology. With TRFT, perhaps within a few years there will be an effective non-drug treatment for all forms of brain cancer – a treatment that could provide a long-term healthy life for patients suffering from this dreaded disease. The Phase II clinical trial cannot begin soon enough for these patients.

New Scientific Paper Referenced: Arendash GW (2025) The Evidence that Brain Cancers Could Be Effectively Treated with In-Home Radiofrequency Waves. *Cancers* 17: 2665.

RF Longevity SE, Phoenix, AZ 85022